Related to cancer and ACT therapeutic targets, knockdown of PDZD8, encoding the mitochondria-associated endoplasmic reticulum membrane protein, has shown to significantly promote anti-tumor activity of sunitinib, an inhibitor of tyrosine kinase receptor used in combination with antioxidant pterostilbene [47], while expression of POU4F1 (Pit-Oct-Unc domain transcription factor) significantly correlated with cancer patient survival and POU4F1 knockdown inhibited proliferation of esophageal squamous carcinoma cells [48]. This evidence concerns the gene POU4F1 and neoplasm.